Bepirovirsen is an experimental antiviral drug developed by GlaxoSmithKline (GSK) designed to treat chronic hepatitis B virus (HBV) infection by aiming for a functional cure, meaning it clears the virus from the body rather than just suppressing it. Chronic hepatitis B affects an estimated 296 million people worldwide and is a leading cause of liver cirrhosis and hepatocellular carcinoma, resulting in about 820,000 deaths annually. Current standard therapies, such as nucleoside analogs (e.g., tenofovir, entecavir) and pegylated interferon, can suppress viral replication but rarely achieve a complete cure, as the virus persists in the form of covalently closed circular DNA (cccDNA) in liver cells. Bepirovirsen, an antisense oligonucleotide, targets viral RNA to reduce hepatitis B surface antigen (HBsAg) levels, potentially enabling the immune system to clear the infection. The U.S. Food and Drug Administration (FDA) is expected to make a decision on Bepirovirsen in 2026, either granting full approval, accelerated approval, or issuing a Complete Response Letter (CRL) denying approval. The outcome will significantly impact GSK's pipeline, the hepatitis B treatment landscape, and patient access to a novel therapy that could reduce long-term reliance on daily antiviral pills. GSK has reported positive Phase 2b trial results, showing that a subset of patients achieved sustained HBsAg loss, a key marker for functional cure, but questions remain about durability, safety, and efficacy across diverse populations. The market resolves to Yes if the FDA grants full or accelerated approval; it resolves to No for a denial, withdrawal, conditional approval, or no decision by the end of 2026.

Historical Context

Chronic hepatitis B has been a global health problem for decades. The virus was discovered in 1965 by Dr. Baruch Blumberg, who later won the Nobel Prize. The first hepatitis B vaccine was approved in 1981, but a functional cure has remained elusive. Current treatments, like nucleoside analogs (first approved in 1998), suppress viral replication but do not eliminate the virus from the liver. The concept of a functional cure, defined as sustained HBsAg loss with undetectable viral DNA, has been a goal since the early 2000s. In 2015, the World Health Organization set targets to reduce hepatitis B deaths by 65% by 2030, but progress has been slow. The FDA has approved only a few new hepatitis B drugs in the last decade, including tenofovir alafenamide (TAF) in 2016, which is a reformulation of an older drug. Bepirovirsen represents a new class of therapy: antisense oligonucleotides that directly target viral RNA. GSK began Phase 1 trials in 2017 and advanced to Phase 2b by 2020. The Phase 2b results, published in The New England Journal of Medicine in 2023, showed that 28% of patients achieved HBsAg loss after 24 weeks of treatment, compared to 0% in the placebo group. However, some patients experienced viral rebound after stopping treatment, raising questions about durability. The FDA's decision in 2026 will be informed by ongoing Phase 3 trials, which are expected to enroll over 1,000 patients globally. Regulatory precedents include the FDA's accelerated approval of other RNA-targeting drugs, like nusinersen for spinal muscular atrophy, which used surrogate endpoints. However, the FDA has been cautious with hepatitis B cures, requiring long-term follow-up data to confirm sustained responses.

Frequently Asked Questions